Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services

Abstract

Summary

Vertebral fractures are independent risk factors for vertebral and nonvertebral fractures. Since vertebral fractures are often missed, the relatively new introduction of vertebral fracture assessment (VFA) for imaging of the lateral spine during DXA-measurement of the spine and hips may contribute to detect vertebral fractures. We advocate performing a VFA in all patients with a recent fracture visiting a fracture liaison service (FLS). Fracture liaison services (FLS) are important service models for delivering secondary fracture prevention for older adults presenting with a fragility fracture. While commonly age, clinical risk factors (including fracture site and number of prior fracture) and BMD play a crucial role in determining fracture risk and indications for treatment with antiosteoporosis medications, prevalent vertebral fractures usually remain undetected. However, vertebral fractures are important independent risk factors for future vertebral and nonvertebral fractures. A development of the DXA technology, vertebral fracture assessment (VFA), allows for assessment of the lateral spine during the regular DXA bone mineral density measurement of the lumbar spine and hips. Recent approaches to the stratification of antiosteoporosis medication type according to baseline fracture risk, and differences by age in the indication for treatment by prior fracture mean that additional information from VFA may influence initiation and type of treatment. Furthermore, knowledge of baseline vertebral fractures allows reliable definition of incident vertebral fracture events during treatment, which may modify the approach to therapy. In this manuscript, we will discuss the epidemiology and clinical significance of vertebral fractures, the different methods of detecting vertebral fractures, and the rationale for, and implications of, use of VFA routinely in FLS.

Summary points

• Vertebral fracture assessment is a tool available on modern DXA instruments and has proven ability to detect vertebral fractures, the majority of which occur without a fall and without the signs and symptoms of an acute fracture.

• Most osteoporosis guidelines internationally suggest that treatment with antiosteoporosis medications should be considered for older individuals (e.g., 65 years +) with a recent low trauma fracture without the need for DXA.

• Younger individuals postfracture may be risk-assessed on the basis of FRAX® probability including DXA and associated treatment thresholds.

• Future fracture risk is markedly influenced by both site, number, severity, and recency of prior fracture; awareness of baseline vertebral fractures facilitates definition of true incident vertebral fracture events occurring during antiosteoporosis treatment.

• Detection of previously clinically silent vertebral fractures, defining site of prior fracture, might alter treatment decisions in younger or older FLS patients, consistent with recent IOF-ESCEO guidance on baseline-risk-stratified therapy, and provides a reliable baseline from which to define new, potentially therapy-altering, vertebral fracture events.

Introduction

Osteoporosis is a chronic bone disease that is characterized by low bone mineral density (BMD), and deteriorated microarchitecture, leading to decreased bone quality and an increased susceptibility to fracture [1]. However, there are substantial diagnostic and treatment gaps in the field of osteoporosis globally, leading to a low percentage of the population worldwide who are at high risk of fracture being adequately assessed and treated for osteoporosis [2, 3]. Remarkably, the treatment gap appears to have widened in recent years (the so-called “crisis in osteoporosis”) likely related to reimbursement, changes to healthcare policy and excessive concerns about very rare side-effects of antiosteoporosis medications, for example osteonecrosis of the jaw (ONJ) and atypical femur fractures (AFF) [4].

One of the most powerful approaches to fracture risk evaluation, and consequently to reduce the burden of fractures, is the fracture liaison service (FLS), in which (usually older) patients with a recent fragility fracture are screened for a high subsequent fracture risk by age, clinical risk factors and by BMD-measurement using DXA [5–8]. Such approaches are set out globally in the IOF Capture the Fracture® Programme [9]. However, using this strategy, prevalent vertebral fractures will not be detected. Importantly, developments in DXA instruments mean that it is now possible, using modern instruments, to detect prevalent vertebral fractures during the DXA assessment, with acquisition of a lateral view of the thoracic and lumbar spine, known as a vertebral fracture assessment (VFA) , which is also called “Lateral Vertebral Assessment”.

Recent guidance from IOF-ESCEO has demonstrated that antiosteoporosis therapy should optimally not just be a question of treatment or no treatment, but that the choice of a specific therapeutic intervention can be informed by the level of an age-dependent baseline fracture probability [10]. Baseline risk, calculated using the FRAX® algorithm, with BMD if available, is substantially (2 to 5 times) higher, depending on site of fractures, number of prior fractures and their recency, as well as by other factors such as dose of corticosteroids [11]. In this context, for both older FLS patients whose general indication for therapy might be modified in terms of specific antiosteoporosis medication issued (e.g., anabolic for very high risk), and for younger FLS patients with treatment directly informed by FRAX probability with BMD, the detection of occult vertebral fractures by VFA might modify the final treatment decision. A further consideration is that a new vertebral fracture occurring on treatment is likely to be an indication for review of antiosteoporosis therapy [12]. Baseline VFA within the FLS care pathway provides knowledge of existing fractures and thus facilitates reliable definition of incident events. In this review article, we will explore the potential role of routine VFA in the FLS, in the context of the wider epidemiology of vertebral fractures, the performance characteristics of VFA for detection of vertebral fractures and, critically, emerging evidence for the clear importance of both site and recency of prior fracture for FRAX-based fracture risk assessment. We conclude with a suggested clinical approach to the use of VFA in FLS, which may improve risk stratification, and the basis for long-term care, in this vital secondary prevention setting.

Epidemiology of vertebral fractures

Prevalence and incidence by age and sex

The burden of vertebral fractures is immense with some prevalence estimates globally as high as 25-50% for individuals over the age of 50 years [13, 14] and with a prevalence, in some studies, higher than that of hip or wrist fracture (Fig. 1) [15]. However, the accurate description of the epidemiology of vertebral fractures is complicated by two main factors.

Fig. 1.

The age distribution of hip, radiographic vertebral and hip fractures, reproduced with permission from Elsevier [15]

First, the fact that 65–75% are clinically “silent” [16] and only 30–40% of vertebral fractures come to medical attention [17]. Underrecognition and underdiagnosis occur, even by radiologists. Gehlbach et al. [18] showed in a population of 934 hospitalized postmenopausal women 60 years and over with chest radiographs that 132 vertebral fractures were diagnosed by two radiology experts, 65 fractures were described in the radiology report, and only 23 in the patient record, and in 25 (18%) antiosteoporotic treatment was started [18]. Similarly, during a systematic review of lateral chest X-rays by an osteoporosis expert at the Geneva University hospital, the prevalence of vertebral fractures was 29%, but only a third had been reported by radiologists [19].

Many VFs are discovered coincidentally on routine imaging. This is a particularly problematic situation when considering that (on plain radiography) the presence of vertebral fractures is often missed [20]. Second, various definitions of vertebral fractures exist, using clinical or morphometric parameters which significantly alter the population measures of disease [21]. The European Vertebral Osteoporosis Study (EVOS) (which included 15,000 individuals from 19 European countries) found an age-standardized population prevalence of 12.2% in women and 12.0% in men (aged 50–79 years) using the morphometric methods of McCloskey and Eastell to define vertebral deformity [21]. The Canadian Multicenter Osteoporosis Study (CaMos, a 5-year follow-up of over 9000 participants) found a similar prevalence of vertebral fractures between the sexes with a male to female prevalence ratio of 1:1 [22]. In this study, the reference norms for vertebral shape was extracted from a subset of the population data, with any parameter greater than 3 standard deviations (SD) away from the mean indicating vertebral deformity within the whole data set. However, findings from the European Prospective Osteoporosis Study (EPOS, participants aged 75–79 years) suggested a higher incidence in men than women (29.3 vs 13.6 fractures per 100 person-years for men and women respectively) [23]. The definition of a vertebral fracture was a vertebra in which there was evidence of a 20% (+ 4 mm) or more reduction in anterior, middle, or posterior vertebral height between films. An additional requirement was that vertebra satisfy criteria for a prevalent deformity (using the McCloskey-Kanis method) in the follow-up film. Finally, the Rotterdam Study found incidences of 1470 and 590 per 100,000 person years in women and men respectively using the McCloskey-Kanis method for vertebral fracture detection [24].

Geographic variation

Geographically, there is marked variation across the European continent with a 3-fold difference in the prevalence of vertebral fracture in different countries, the highest being in Scandinavia (though this was partially explained by factors such as physical activity levels and measures of adiposity [21]). Geographical variation is observed across Latin America in the Latin American Vertebral Osteoporosis Study (LAVOS) which found an overall prevalence of 14.8% across the continent, but a significant difference between the highest country rate (in Mexico) and the lowest (in Puerto Rico) [25]. In Asian studies, there is generally greater variation in prevalence rates across the region, with a 1.42 difference between the highest prevalence rates in Vietnam and the lowest rates in China [26]. Across the globe, the highest age-standardized rates are seen in South Korea, USA, and Hong Kong, with the lowest rates in the UK [26].

Vertebral fractures and mortality

A vital element in the descriptive epidemiology of vertebral fractures is the associated increase in mortality which persists for more than a year postfracture [27, 28]. In the UK, a study of a large, primary database observed a 12-month survival rate in women of 86.5% (vs 93.6% expected) and 5-year survival of 56.5% (vs 69.9% expected).

Clinical significance of vertebral fractures

Vertebral fracture and risk of further fractures

Previous studies have shown that prevalent vertebral fractures detected using spinal radiographs are predictive of future vertebral fractures and nonvertebral fractures [29, 30]. Black et al. [29] reported in the Study of Osteoporotic Fractures, a prospective study of 9704 women aged 65 years or older that prevalent vertebral fractures were associated with a 5-fold increased risk of sustaining a further vertebral fracture. Furthermore, the risks of hip and any nonvertebral fractures were increased with baseline prevalent fracture, with relative risks (RR) of 2.8 (95% CI 2.3, 3.4) and 1.9 (95% CI 1.7, 2.1), respectively. These associations remained significant after adjustment for age and calcaneal BMD [29]. Moreover, more severe or greater number of vertebral fractures were associated with higher fracture risk than milder or fewer vertebral fractures [29, 31, 32], independent of BMD [32]. In a large multinational study (n = 2725 postmenopausal women), the RR of new vertebral fracture increased with the number of baseline vertebral fractures [31]. Indeed, in subjects with a VF at baseline of the study, the risk of a new vertebral fracture within 1 year was 5-fold that of women who did not have a baseline vertebral fracture (RR = 5.1, 95% CI 3.1–8.4). In the overall population, the incidence of a new vertebral fracture in the subsequent year after suffering an incident vertebral fracture was 19.2% (95% CI 13.6–24.8%) [31]. Thereby, the presence of a vertebral fracture greatly increases the risk of sustaining subsequent vertebral fractures, a phenomenon often referred to as “vertebral fracture cascade” [31, 33, 34]. In the retrospective case-series (n = 113, 79.6% of women, median age 73) performed by Che et al. [34], vertebral fracture cascade was defined as an occurrence of at least three vertebral fractures within 1 year. Several authors found that those with at least one prevalent vertebral fracture on VFA had increased hazard ratios (HR) for incident clinical fractures [35–37]. Prince et al. [37] reported, in the setting of a randomized clinical trial “Calcium Intake Fracture Outcome Study (CAIFOS)”, that those with one or more prevalent vertebral fractures on VFA had increased HR for incident clinical spine (HR = 3.81; 95% CI 2.26–6.43, p < 0.05), hip (HR = 1.77; 95% CI 1.07–2.92, p < 0.05), and any fracture (HR = 1.54; 95% CI 1.09–2.16, p < 0.05), independent of age and calcium/placebo treatment [37].

Vertebral fractures and quality of life

Vertebral fractures have many potential consequences for the individual beyond economic cost; these risks include functional limitation, loss of independence, pain, impaired quality of life, higher inpatient healthcare utilization and diminished lifespan [38–43]. Health-related quality of life (HRQoL) has become an important tool used to assess the burden of disease imposed by chronic disease or disease events. Several studies have investigated the associations between HRQoL and back pain with prevalent vertebral fracture, detected by spine radiographs, but just a few have been population-based and have used VFA for diagnosing vertebral fracture [38–40, 44]. Among 1681 women and 1026 men aged 75–80 years participating in a population-based cross-sectional study (the Tromsø Study 2007–2008), VF was identified by VFA using DXA. Prevalent vertebral fracture was associated with back pain and reduced HRQoL in women, but not in men [44]. In a study of 751 women with and without vertebral fractures, diagnosed by spine radiographs, quality of life was assessed using the quality of life questionnaire of the International Osteoporosis Foundation (QUALEFFO-41), a measure containing questions in the domains of pain, physical function, social function, general health perception, and mental function. Women with vertebral fracture had significantly worse scores, which increased with number of vertebral fractures [45]. In a metaanalysis of 16 observational studies (including only one small study with men) including 3131 older osteoporotic patients with and without vertebral fractures the physical HRQoL was reported to be worse in people with vertebral fracture, even after accounting for age differences [46].

Studies investigating time since onset of vertebral fracture, and its effect on HRQoL, have shown that a residual effect lasts for up to 7 years postfracture [47, 48]. Furthermore, Johansson et al. [49] have shown, in a recent population-based cross-sectional study of 3028 Swedish women aged 78.8 years, that a (self-reported) clinical vertebral fracture was associated with lower physical HRQoL (12-Item Short-Form Health Survey (SF-12)). Moreover, the association remained for up to 18.9 years independently of covariates such as age, weight, height, smoking, prior stroke, mental HRQoL, grip strength, and lumbar spine BMD [49]. However, other studies have reported the contrary with improvement of the HRQoL within 2 to 4 years after onset of vertebral fracture [50, 51]. The effect of recent VFs on HRQoL as measured by SF-12 in younger and older women has been investigated in a cohort of 86,128 postmenopausal women and the impact on physical HRQoL was similar between women < 65 compared with those ≥ 65 years of age [52]. There is some evidence that if more individuals affected by vertebral fractures were to be identified and were to receive treatment, the HRQoL would be improved [53]. Thus overall, it is apparent that vertebral fractures have a major impact on quality of life for many years after their occurrence.

Methods for detection and interpretation of vertebral fractures

DXA VFA method

Vertebral fracture assessment (VFA), using DXA, has been proposed as an alternative approach for the identification of vertebral fracture [54]. It consists of a lateral radiographic image of the thoracic and lumbar spine which can be easily and rapidly acquired via DXA scanning. The current conventional practice for initial vertebral fracture assessment is the use of the spinal radiographs [55] and images are taken from AP and lateral views of the thoracic and lumbar spine; more recent recommendations, for example the European Guidelines, accommodate the DXA-VFA approach [56]. Conventional spinal radiograph has remained the (gold) standard to which DXA-VFA images are compared in studies establishing the validity and reproducibility of VFA [57–61]. There is good agreement between DXA-VFA and spinal radiographs (κ: 0.74–0.96) for presence of vertebral fracture using the semiquantitative approach [62, 63]. In comparison with conventional radiographs, DXA-VFA has several distinct advantages including lower cost, lower radiation exposure, less obliquity [54], and greater convenience for patients given it can be performed at the same time as BMD measurements. A typical patient may receive an effective dose of 0.7 millisievert (mSv) for a standard AP lumbar spine view radiograph [64] compared with ~0.01 mSv for a fan beam DXA [65], and < 0.001 mSv for a pencil beam DXA [66]. VFA is a low dose technique with doses reported to be from 0.002 to about 0.05 mSv.

However, limitations of DXA-VFA include reduced image resolution with cortical edges and endplates, leading to fewer visualized vertebra, particularly affecting the thoracic spine between T4 and T6 [57, 60, 67], and reduced ability to detect “mild” fractures [58].

In a systematic review, the diagnostic accuracy of DXA-VFA was compared with that of spinal radiography for detection of VFs [68]. VFA was found to have a reasonable sensitivity and a much better specificity for VF detection on a per-vertebra level (0.70–0.93 and 0.95–1.00 respectively), and the sensitivity and specificity on a per-patient basis were 0.65–1.00 and 0.74–1.00 respectively [68]. Moreover, DXA technology continues to evolve, from the 1st generation machines using pencil beam to later models employing a wide or narrow fan beam, which has shortened the acquisition time and improved image quality [69]. Whilst there has been no direct comparison between the different models of DXA scanners with regards to VF detection, there have been numerous studies using different models of DXA scanners comparing with radiograph [60, 70, 71]. Diacinti and colleagues [70] used a later model of DXA scan, the Lunar iDXA, which yielded a much higher sensitivity and specificity per vertebra, 96.97% and 99.91% respectively, and equally high sensitivity and specificity on a per patient basis, 96.83% and 98.66% respectively. In fact, both the sensitivity and specificity increased further when focused on those ≥ 65 years on a per-vertebra and per patient bases [70]. For Hologic DXA scanners, older models such as Delphi C/W yielded a low sensitivity (47%) but a high specificity per vertebra (99%) [60, 70]. The use of Hologic Discovery, a later model, improved the sensitivity and specificity per vertebra to 83.6% and 99.1% respectively [71]. Computer-based deep learning methods have been developed for VFA, and a recent study including over 12,000 VFAs has reported an area under the receiver operating characteristic curve of 0.94 (95% confidence interval [CI]: 0.93, 0.95) for vertebral fracture detection [corresponding to a sensitivity of 87.4% (534 of 611) and specificity of 88.4% (2838 of 3211)] and performed comparably to the study radiologists (all who had more than 10 years of experience) [72].

Other technologies for targeted and opportunistic identification of vertebral fractures: CT, MRI, and SPECT

CT

Whilst the focus of this review is on the use of DXA-VFA in FLS, it should be recognized that several other technologies might be usefully incorporated into a comprehensive strategy for vertebral fracture detection. One potential source of vertebral fracture case detection is computed tomography (CT). Scans of the thorax, pelvis, and abdomen often include spinal elements; however, vertebral fractures may be present but not identified or reported. Indeed, it has been estimated that only 13–16% of retrospectively confirmed vertebral fractures on CT scans are reported [73–75], likely due to the fact that they are incidental findings and not the primary purpose for the investigation. However, the prevalence and incidence of VFs can be high in studies for other diseases, as has been shown in a large survey of subjects with COPD [76]. Studies have shown a high correlation between trabecular vertebral attenuation values on CT images and DXA BMD values [77–80], however the high radiation dose (typical effective dose for an adult abdominal CT is 8 mSv) [69] and higher cost mean that CT is best placed as an opportunistic secondary modality, rather than as a primary assessment tool. Recent advances in computer processing and computer vision have led to development of computer-based deep learning or active shape modelling to identify fractures. The accuracy afforded by such approaches is 89–97% [81–83].

MRI

Magnetic resonance imaging (MRI) permits acquisition of 3D images of the body, including characterization of vertebral fractures [84–86]. An advantage over CT is the lack of ionizing radiation and that information can be gained on recency of fracture, from the presence of edema; a major disadvantage is the much longer scan times, danger posed by ferromagnetic implants and frequently claustrophobia-inducing gantry. With recent technological advances, newer sequences and higher field strength over the last decade, MRI now represents a further option to explore bone microarchitecture [87] and the role of bone marrow adiposity in osteoporosis using diffusion weighted imaging and MR spectroscopy [88]. The place of MRI in opportunistic identification of vertebral fractures is as yet not well defined, and more robust evidence from large, prospective, multicenter studies is needed to validate the results of small translational studies [54, 87].

SPECT

Single-photon emission computed tomography (SPECT) is a sensitive diagnostic tool that can aid the identification of bony abnormalities that may be difficult to adequately characterize through the use of other imaging modalities alone. An example is Bertolotti’s Syndrome [89, 90]. In recent years, the use of SPECT has been compared to MRI in terms of fracture detection and management [91, 92]. In these small clinical studies, SPECT appears to be comparable to MRI in detecting fractures, particularly in the acute phase, and could be considered if MRI is contraindicated and plain radiography does not provide diagnostic certainty. Given the more specialist use of SPECT, it is unlikely to be usefully incorporated into an opportunistic pathway for detection of vertebral fractures.

Classification of vertebral fracture: QM, SQ, Genant, and ABQ methods

The classification of vertebral fracture has evolved in the last six decades, with early works by Hurxthal [93] and Barnett and Nordin [94] using a morphometric basis, in which the focus is vertebral dimension. There have been attempts over the years to develop the morphological approach [95, 96], in which the focus is the changes observed at the vertebral endplate (including cortical changes). Pure morphometric measurement focuses on six points on the vertebral body: the anterior, middle, and posterior point of the upper and inferior endplates. The relative height reduction between the anterior or middle section of the upper and inferior endplates points compared to height of the posterior section or the height reduction of posterior section in comparison to the adjacent vertebra will give rise to the diagnosis of vertebral fracture. This allows the type of deformity to be described as wedge, compression, and biconcavity. There are numerous proposed quantitative morphometric (QM) methods to aid the classification of severity of the fracture [20, 97, 98]. However, the most widely adopted approach is the semiquantitative (SQ) method proposed by Genant and colleagues in 1993 [99]. This approach requires a lateral image of either thoracic or lumbar spine then visually grade the height of the vertebra. The vertebra is graded as normal (grade 0), mildly deformed (grade 1: 20–25% reduction in anterior, middle, or posterior height with 10–20% reduction of vertebra area), moderately deformed (grade 2: 25–40% reduction in anterior, middle, or posterior height with 20–40% reduction of vertebra area), and severely deformed (grade 3: ≥ 40% reduction in anterior, middle, or posterior height with ≥ 40% reduction of vertebral area) [99]. The Genant SQ method includes visual assessment of height loss alongside with morphological change and assessment of the endplate, which incorporates a qualitative element. The algorithm-based qualitative (ABQ) method, proposed in 2004, was developed after observing new vertebral fractures always involved radiological changes at the vertebral endplate [95]. The ABQ method follows a series of steps which then results in three potential outcomes: (a) normal, (b) osteoporotic fracture, and (c) nonfracture deformity [95]. The ABQ approach fundamentally assumes all vertebral fractures will involve changes at the endplate therefore taking a morphologic approach but does not include changes in height [95].

Limitations and thresholds in diagnosis of fracture

Both the QM method and morphological approaches have constraints that reduce their usefulness in clinical setting. One major disadvantage of QM is its inability to distinguish nonfracture causes of vertebral deformities including Scheuermann’s disease, Schmorl’s nodes, development deformities, and Cupid’s bow from fracture [54, 97]. This pitfall can be avoided by the use of an experienced clinician [97], however this may not be achievable in clinical practice at all times. Unfortunately, this weakness also affects the morphological approach [100], in which the ability to differentiate x-ray beam rotation/artefact from endplate depression and cortical buckling is of paramount importance [54]. For vertebral deformity severity stratification, Genant SQ has the distinct advantage of overcoming the above constraint and allowing interpretation of follow-up radiographs as it has the capability to assess delta change in vertebral height [54]. The key to the ABQ method proposed by Jiang and colleagues [95] is that it has given structure to a qualitative method [100] which can be subjective. The structured qualitative approach will therefore improve the likelihood of reproducibility.

The prevalence of vertebral fracture will differ depending on the method used for classification. Recently, the Rotterdam Study found the prevalence of vertebral fracture was over three times higher using QM method compared to ABQ method [101]. The disparity was reduced in the CaMos study, using Genant SQ method in comparison to a modified ABQ (mABQ) approach, with Genant SQ method vertebral fracture prevalence just over twice as high as mABQ [102]. Here, the mABQ method incorporated the degree of vertebral height reduction as part of diagnostic criteria [102]. There is also variation in vertebral fracture site, Genant SQ/QM vertebral fractures were predominately located in mid-thoracic spine, whereas ABQ VFs were mostly in the thoracolumbar junction [101, 102]. Overall, the agreement between morphometric and morphologic approaches for grade 2 or 3 vertebral fractures is high. Deng and colleagues [103] found participants with grades 2 and 3 Genant SQ VF and grades 2 and 3 endplate/cortex fracture to have similar BMD, and both showed worsening BMD as the severity of fracture increased. In the same study, comparable prevalence of vertebral fractures was found using both methods for grades 2 and 3, however there was noticeable disparity at grade 1 between the two methods [103]. In The Rotterdam Study, the intermethod agreement between QM method and ABQ method would increase by 2-fold when mild fractures were excluded [101]. Mild fractures were defined as deformities with height loss but intact endplates, using both methods.

Significance of grade 1 fractures

It remains uncertain whether mild vertebral fracture such as grade 1 Genant SQ VF should be included in fracture risk assessment. Recent data from Sweden showed grade 1 Genant SQ VFs was associated with increased risk of developing fracture and was independent of age, clinical factors, and femoral neck BMD in older women [104]. However, in the CaMos study, whilst prevalent grade 1 Genant SQ VF was associated with incident Genant SQ VF compared with those without prevalent Genant SQ VF, but grade 1 Genant SQ VF was not associated with incident nonvertebral MOF compared to those without prevalent Genant SQ VF [102]. In fact, prevalent grade 1 mABQ VF had a higher association with incident Genant SQ VF than grade 1 Genant SQ VF [102]. On the surface, this suggests that endplate depression or cortical buckling may have a stronger association with future fracture risk than height loss. However, it has been observed that some Genant SQ VF do not have endplate or cortical involvement [102, 103]. Deng and colleagues [103] found many grade 1 Genant SQ VF had no endplate/cortex involvement, and a number of grade 2 Genant SQ VF did not have endplate/cortex involvement either. This opens the debate whether the categorical assumption that all vertebral fractures will have endplate involvement is true at all times. Further research into the pathogenesis of these vertebral changes and their specific associations is needed. Both the ISCD and the IOF recommend the use of Genant SQ method in vertebral fracture identification [54, 105]. The Vertebral Fracture Initiative from IOF recommend the use of the term “fracture” and avoid using apparent synonyms such as “collapse” for clarity [54], a concept supported by national guidelines [106]. It also clearly states the need for grading the severity of the fracture alongside the number of vertebral fractures [54]. Given the absence of straightforward data on the increased fracture risk after a prevalent grade 1 fracture and the uncertainty to detect grade 1 fractures, and the high propensity for agreement between grade 2 and grade 3 VFs using either morphometric or morphologic approach, in clinical practice it would be prudent to follow a threshold of grade 2 (≥ 25%) (or 3 ≥ 40%), vertebral height loss as described by the Genant SQ method for identification of vertebral fracture, both in men and women. Nevertheless, when there is doubt about the presence or absence of a vertebral fracture, we suggest additional imaging techniques, which would most usually be a conventional radiograph.

Current indications for vertebral fracture assessment by DXA

The International Society for Clinical Densitometry (ISCD) has provided recommendations on defining and reporting fractures on VFA in its official position statements [105]. For the ISCD, the methodology used for vertebral fracture identification should be similar to standard radiological approaches and be provided in the report. Fracture diagnosis should be based on visual evaluation and include assessment of grade/severity and morphometry alone is not recommended because it is unreliable for diagnosis. Finally, for the ISCD, the Genant visual semiquantitative method is the current clinical technique of choice for diagnosing vertebral fracture with VFA, and the severity of deformity may be confirmed by morphometric measurement if desired [105]. Indications for following VFA with another imaging modality are also described, and it is important to recognize that VFA is designed to detect vertebral fractures and not other abnormalities. The IOF-ESCEO has recently provided European guidance for the diagnosis and management of osteoporosis in postmenopausal women including recommendations on VFA [56]. Lastly, the National Osteoporosis Foundation (NOF) released, in 2014, a clinician’s guide to prevention and treatment of osteoporosis including indications for vertebral imaging [107]. The recommendations of all three are summarized in Table 1.

Table 1.

Indications for vertebral fracture assessment (VFA) by DXA to detect vertebral fracture

International Society for Clinical Densitometry (ISCD) (ref 105)	International Osteoporosis Foundation- The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (IOF-ESCEO) (ref 56)	National Osteoporosis Foundation (NOF) (ref 107)
Lateral Spine imaging with Standard Radiography or Densitometric VFA is indicated when T-score is < -1.0 and of one or more of the following is present: • Women age ≥ 70 years or men ≥ age 80 years • Historical height loss > 4 cm (> 1.5 inches) • Self-reported but undocumented prior vertebral fracture • Glucocorticoid therapy equivalent to ≥5 mg of prednisone or equivalent per day for ≥ 3 months Recommendations from the ISCD adult Official Position Statement 2019	VFA should therefore be considered in high-risk individuals, using either spine radiographs or lateral spine DXA imaging in postmenopausal women: • History of ≥ 4 cm height loss • Kyphosis • Recent or current long-term oral glucocorticoid therapy, • BMD T-score ≤ − 2.5. • It should also be considered in individuals with a history of non-vertebral fracture Recommendations from the IOF-ESCEO: European guidance for the diagnosis and management of osteoporosis in postmenopausal women	Vertebral imaging should be performed: In all women age 70 and older and all men age 80 and older if BMD T-score is ≤ − 1.0 at the spine, total hip, or femoral neck. In women age 65 to 69 and men age 70 to 79 if BMD T-score is ≤ − 1.5 at the spine, total hip, or femoral neck. In postmenopausal women and men age 50 and older with specific risk factors: • Low-trauma fracture during adulthood (age 50 and older) • Historical height loss (difference between the current height and peak height at age 20) of 1.5 in. or more (4 cm) • Prospective height loss (difference between the current height and a previously documented height measurement) of 0.8 in. or more (2 cm) • Recent or ongoing long-term glucocorticoid treatment If bone density testing is not available, vertebral imaging may be considered based on age alone.

Clinical approach to routine VFA in FLS secondary fracture prevention

Value of VFA in secondary prevention

VFA is currently underused globally, possibly partly because its utility has been unclear to healthcare providers and payers. Indeed, the degree to which VFA is reimbursed varies markedly across global health care systems. However, in the nonFLS context, VFA has shown added value to clinical diagnosis of osteoporosis and its subsequent management [108–110]. Studies have shown that the addition of VFA altered the therapeutic management of 3–30.8% of cases [111–113]. Other studies have also demonstrated that prevalent vertebral fracture identified from VFA images predict subsequent fractures independent of BMD and other risk factors [36, 114]. The use of VFA enhances the assessment especially for those in the normal and osteopenic BMD range, where depending on the guideline followed, medication is unlikely to be initiated in the absence of demonstrable fracture history. Such considerations support the notion that VFA might be regarded as a routine part of DXA assessment regardless of the setting in primary or secondary prevention.

VFA in FLS: previous work

Although worldwide many FLS exist, only a small number of studies have been performed on the additional value of VFA in patients with a fragility fracture and a DXA-measurement. However, it is important to note that, as will be described below, criteria for intervention may not uniformly depend upon the presence of a recent prior fracture, but may be further modified by the presence or absence of densitometrically confirmed osteoporosis. Within FLS there is clearly potential to further refine risk assessment using VFA: A UK FLS found a quarter of patients presenting with a nonhip nonvertebral fragility fracture have an undiagnosed vertebral fracture [109]. Furthermore, only 49.5% of those with undiagnosed vertebral fractures had BMD measurements diagnostic of osteoporosis [109]. Likewise Van der Velde and colleagues [110] found 20.9% participants with normal BMD had ≥ 1 VF, and 27.7% for those with osteopenia and the diagnosis for vertebral fractures from 2.3 to 26.2% (p < 0.001) and for grade 2 or more from 0.9 to 14.7% (p < 0.001). The first study on the use of VFA in the FLS is from Glasgow [115]: in a prospective study in 377 patients with a low trauma nonvertebral fracture, VFs were found in 83 patients (25%); in 37 patients, 2 or more vertebral fractures were found. In osteoporotic patients, VFs were found in 42%, and in 19.8% of osteopenic patients. Overall in the study, a change of management occurred in 8.9% of patients because of their underlying vertebral fracture. In a recent study from France, 141 patients 50 years or over with a recent fragility fracture were enrolled: 24 (21%) of the patients had a one or more VF diagnosed using VFA [116]. The total number of VFs was 30: grade 1 in 20 patients, grade 2 in 7 patients (23%), and grade 3 in 3 patients (10%). In 18 out of the 24 patients with at least one VF, osteoporosis medication was adapted (starting antiosteoporotic drugs in 16 patients, and intensification in 2 patients).

Thus, there are two FLS studies that showed that vertebral fractures can be detected in around 20% of patients, and in around 10% has consequences for treatment. Furthermore, in a Dutch study, it was shown that after the introduction of local guideline on the use of VFA in addition to DXA, the diagnosis of vertebral fractures increased from 2.2 to 26.2% for grade 1, and from 0.9 to 14.7% to grade 2. Including patients with osteopenia and a vertebral fracture increased the percentage of patients with an antiosteoporosis drug-treatment indication from 31.0 to 38.4% (a 25% increase): this again shows that with VFA more vertebral fractures were diagnosed, leading to the recognition of more high-risk patients and (thus) antiosteoporosis treatment indications. But also very importantly, the study showed that implementation was feasible: performing DXA increased from 4.6 to 97.1% [110].

Clinical approach to VFA in FLS

Whether DXA-VFA changes management decisions in FLS clearly depend upon local or national policy with regard to the criteria for treatment with antiosteoporosis medications. For example, in some guidelines, such as the Scottish SIGN, even after FRAX assessment or prior fracture, treatment is suggested when the BMD T-score is − 2.5 or below. The limitations of this approach have been documented previously [117]. The recently published IOF-ESCEO European guidelines [56], consistent with the majority of guidelines internationally [118], suggest that in the context of a low trauma fracture, in older patients (> 65 years), antiosteoporosis treatment can usually be recommended without further assessment of BMD. Thus in this context, it might be considered that additional knowledge of prevalent vertebral fractures would be unlikely to change treatment decisions. Furthermore, in the calculation of fracture probability using FRAX, once prior fracture has been ticked, there is no means of incorporating further prior fractures as an input variable, which might otherwise be used to modify the approach in younger women, in whom commencement of treatment may be decided on FRAX probability [119]. However, it is apparent from previous and more recent work that both the number, timing, and site of prior fractures influence the risk of a future fracture [11, 120–122]. Thus a prior vertebral fracture conveys a greater risk of future vertebral or hip fracture than does a prior wrist fracture [122]; fracture risk increases markedly immediately after an index fracture and wanes over 2 years or so, to a more steady level which is still above that prior to the index fracture event [11]. The importance of these modifications has been recognized in the publication of adjustment factors for the FRAX algorithm [11], which allow the attending physician to account for recency and site of prior fracture in treatment decisions in the FLS. Furthermore, guidance recently published by IOF-ESCEO has set out new approaches to the stratification of treatment by baseline fracture risk [10]. Here, whilst the criteria for treatment are established on the basis of the current European guidelines, the decision as to which medication should be used is informed by an individual’s fracture risk, derived using the FRAX calculator. For those at high-risk, antiresorptive therapy such as an oral or intravenous bisphosphonate may be recommended, but for those at very high risk (which might be reached through the detection of a vertebral fracture), an anabolic-first strategy may be employed. Consistent with the European guidelines, women 65 years or older with a recent low trauma fracture will usually warrant treatment regardless of their calculated FRAX probability, but modification of FRAX probability according to recency and site of fracture may push them into the very high-risk category, with anabolic therapy thus suggested. In younger patients, where the treatment decision is based on FRAX probability, this kind of modification (for example presentation with a wrist fracture but evidence of a vertebral fracture on DXA-VFA) might lead to movement between risk categories to either indicate treatment or type of treatment. Finally, an incident vertebral fracture on treatment may well be a strong indication that alternative treatment is required. Given that vertebral fractures are often silent, baseline detection of vertebral fractures using DXA-VFA in the FLS, provides vital information that allows the treating physician to classify any subsequent fractures reliably as incident rather than prior events [12]. Finally, the presence of vertebral fractures may influence treatment duration, with a higher risk of refracture following treatment cessation [123].

Conclusion and future directions

Despite evidence for the clinical effectiveness of secondary fracture prevention for vertebral fractures, translation of this knowledge into the real-world setting remains disappointing. The IOF Capture the Fracture Best Practice Framework, the leading global initiative aiming to break the fragility fracture cycle, defines essential and aspirational elements of service delivery for fracture care [5]. Other organizations such as the European League Against Rheumatism (EULAR) and the European Federation of National Associations of Orthopaedics and Traumatology (EFORT) have also recognized the importance of optimal acute care for the patients aged 50 years or over with a recent fragility fracture and the prevention of subsequent fractures in high-risk patients [7]. The centerpiece of the IOF Capture the Fracture campaign is the Best Practice Framework, which has 13 standards across five domains and these set an international benchmark for FLS. In a questionnaire-based study that aimed to capture the evidence for the actual implementation of each standard in populations and centers where a FLS had been set up [9], it was found that there were marked differences by domain with secondary fracture prevention best delivered for hip fractures and least for vertebral fractures. The findings show that secondary fracture prevention in the vertebral fracture group remains suboptimal, and that ongoing work is needed to close this care gap even within established services. Strategies to overcome this profound gap could include training for radiology trainees and specialists under vertebral fracture educational programs provided for by international organizations such as the ISCD and IOF. Furthermore, the importance of vertebral fractures is clearly recognized within the IOF/FFN/NOF patient level key performance indicators for FLS [124].

These studies illustrate that detecting prevalent vertebral fractures in patients with fragility fractures may help to close or at the very least narrow the care gap in fracture care [125, 126].

In conclusion, we propose that DXA-VFA be performed in all patients visiting a FLS:

• To detect subclinical vertebral fractures, which may modify risk category and thus commencement or type and duration of therapy, depending on age and local criteria for intervention;

• To provide baseline assessment, based on which later incident vertebral fractures can be discriminated from prevalent fractures, critical to optimal treatment monitoring.

Compliance with ethical standards

Conflict of interest

WFL: received fees for lectures and advisory boards from Amgen, Eli Lilly, UCB, Pfizer, Galapagos and Curaphar; JZ: no conflict of interest; NRF: no conflict of interest; NCH: reports consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, UCB, Kyowa Kirin, Consilient Healthcare, Radius Health and Internis Pharma. CC: received lecture fees and honoraria from Amgen, Danone, Eli Lilly, GSK, Kyowa Kirin, Medtronic, Merck, Nestlé, Novartis, Pfizer, Roche, Servier, Shire, Takeda and UCB. MKJ: received fees for lectures and advisory boards from Amgen, UCB, KLA: Amgen, Astellas, Chugai, Renapharma, UCB.